⚙️ Traces from the dawn of innovation
FDA Approves Eversense E3: Revolutionary Glucose Monitoring
- What: The FDA approved the Eversense E3, an implantable continuous glucose monitoring system for diabetes management.
- Where:
- When: February 2022
In February 2022, a groundbreaking shift in diabetes management occurred when the FDA approved the Eversense E3, an implantable continuous glucose monitoring (CGM) system.
This innovative device features a wearable transmitter that continuously tracks glucose levels, offering a new level of convenience for those managing diabetes.
What makes the Eversense E3 particularly intriguing is its calibration process. Users must perform fingerstick calibrations twice daily for the first 21 days, and then just once daily thereafter. This ensures accuracy while reducing the burden of frequent calibrations.
The implantable nature of the Eversense E3 means it can remain in place for an extended period, providing consistent monitoring without the need for regular sensor replacements, unlike traditional CGM systems.
As technology advances, devices like the Eversense E3 offer hope for improved quality of life for millions of individuals managing diabetes. This approval marks a significant step forward in making diabetes management easier and more efficient.
Did You Know?
The Eversense E3 is designed to be implanted under the skin, allowing for up to 6 months of continuous glucose monitoring without the need for sensor replacement.